Epidemiology of Candidemia in Latin America: A Laboratory-Based Survey

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Nucci, Marcio ^a   Queiroz Telles, Flavio ^b   Alvarado Matute, Tito ^c   Tiraboschi, Iris Nora ^d   Cortes, Jorge ^e   Zurita, Jeannete ^f   Guzman Blanco, Manuel ^g   Santolaya, Maria Elena ^h   Thompson, Luis ⁱ   Sifuentes Osornio, Jose ^j   Echevarria, Juan I ^k   Colombo, Arnaldo L ^l  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c Hospital Escuela   (Honduras)

^d HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^e UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^f PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^g Hospital Vargas de Caracas   (Venezuela)

^h UNIVERSITY OF CHILE   (Chile)

ⁱ UNIVERSIDAD DEL DESARROLLO   (Chile)

^j INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^k UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^l FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; FLUCONAZOLE; VORICONAZOLE;

AGE DISTRIBUTION; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; ORGANISMS BY GEOGRAPHICAL DISTRIBUTION; OUTCOME ASSESSMENT; PICHIA GUILLIERMONDII; PROSPECTIVE STUDY; SOUTH AND CENTRAL AMERICA; SPECIES DISTRIBUTION; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGICAL MONITORING; FLUCONAZOLE; HUMANS; INCIDENCE; INFANT; LATIN AMERICA; MIDDLE AGED; PROSPECTIVE STUDIES; SPECIES SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 84875100579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059373     Document Type: Article

References (42)

1. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, et al. (2011) Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6: e24198.
2. Pfaller MA, Diekema DJ, (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
3. Chalmers C, Gaur S, Chew J, Wright T, Kumar A, et al. (2011) Epidemiology and management of candidaemia-a retrospective, multicentre study in five hospitals in the UK. Mycoses 54: e795-e800.
4. Arendrup MC, (2010) Epidemiology of invasive candidiasis. Curr Opin Crit Care 16: 445-452.
5. Liu CY, Liao CH, Chen YC, Chang SC, (2010) Changing epidemiology of nosocomial bloodstream infections in 11 teaching hospitals in Taiwan between 1993 and 2006. J Microbiol Immunol Infect 43: 416-429.
6. Poikonen E, Lyytikainen O, Anttila VJ, Koivula I, Lumio J, et al. (2010) Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 10: 312.
7. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, et al. (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48: 1695-1703.
8. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, et al. (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 37: 1612-1618.
9. St-Germain G, Laverdiere M, Pelletier R, Rene P, Bourgault AM, et al. (2008) Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 19: 55-62.
10. Zilberberg MD, Shorr AF, Kollef MH, (2008) Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 29: 978-980.
11. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, et al. (2006) Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 44 1977-1981: 44/6/1977.
12. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, et al. (2005) Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43: 1829-1835.
13. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, et al. (2004) Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 38: 311-320.
14. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, et al. (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37: 634-643.
15. Richet H, Roux P, Des CC, Esnault Y, Andremont A, (2002) Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 8: 405-412.
16. Colombo AL, Nucci M, Salomao R, Branchini ML, Richtmann R, et al. (1999) High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 34: 281-286.
17. Antunes AG, Pasqualotto AC, Diaz MC, d'Azevedo PA, Severo LC, (2004) Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns. Rev Inst Med Trop Sao Paulo 46: 239-241.
18. Aquino VR, Lunardi LW, Goldani LZ, Barth AL, (2005) Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis 9: 411-418.
19. Colombo AL, Nucci M, Park BJ, Nouer SA, Arthington-Skaggs B, et al. (2006) Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 44: 2816-2823.
20. Passos XS, Costa CR, Araujo CR, Nascimento ES, Souza LK, et al. (2007) Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital. Mycopathologia 163: 145-151.
21. Motta AL, Almeida GM, Almeida Junior JN, Burattini MN, Rossi F, (2010) Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex. Braz J Infect Dis 14: 441-448.
22. Rodero L, Davel G, Soria M, Vivot W, Cordoba S, et al. (2005) [Multicenter study of fungemia due to yeasts in Argentina]. Rev Argent Microbiol 37: 189-195.
23. Cordoba S, Vivot W, Bosco-Borgeat ME, Taverna C, Szusz W, et al. (2011) Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol 43: 176-185.
24. Lopez ML, Tiraboschi IN, Schijman M, Bianchi M, Guelfand L, et al. (2012) [Fungemia in hospitals of the City of Buenos Aires, Argentina]. Rev Iberoam Micol 29: 144-149.
25. Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A, Colombo AL, (2010) Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 51: 561-570.
26. Clinical and Laboratory Standards Institute (2012) Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth Informational Supplement (M27-S4) Clinical and Laboratory Standards Institute, Wayne, PA.
27. Nguyen MH, Clancy CJ, Yu VL, Yu YC, Morris AJ, et al. (1998) Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 177: 425-430.
28. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, et al. (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23: 317-322.
29. Arendrup MC, Fuursted K, Gahrn-Hansen B, Jensen IM, Knudsen JD, et al. (2005) Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43: 4434-4440.
30. Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, et al. (2002) European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 51: 297-304.
31. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, et al. (2002) Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 45: 141-145.
32. Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, et al. (2003) Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 22: 254-257.
33. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, et al. (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317.
34. Moretti ML, Trabasso P, Lyra L, Fagnani R, Resende MR, et al. (2012) Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil. Med Mycol Aug 27 [Epub ahead of print].
35. Pereira GH, Muller PR, Szeszs MW, Levin AS, Melhem MS, (2010) Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species. Med Mycol 48: 839-842.
36. Sampaio Camargo TZ, Marra AR, Silva CV, Cardoso MF, Martino MD, et al. (2010) Secular trends of candidemia in a tertiary care hospital. Am J Infect Control 38: 546-551.
37. Colombo AL, Garnica M, Aranha Camargo LF, Da Cunha CA, Bandeira AC, et al. (2012) Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals. Med Mycol 51: 38-44.
38. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, et al. (2005) Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 41: 975-981.
39. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, et al. (2012) Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in atlanta and Baltimore, 2008-2011. Clin Infect Dis 55: 1352-1361.
40. Medeiros EA, Lott TJ, Colombo AL, Godoy P, Coutinho AP, et al. (2007) Evidence for a pseudo-outbreak of Candida guilliermondii fungemia in a university hospital in Brazil. J Clin Microbiol 45: 942-947.
41. Duran-Valle MT, Gago S, Gomez-Lopez A, Cuenca-Estrella M, Jimenez Diez-Canseco L, et al. (2012) Recurrent Episodes of Candidemia due to Candida glabrata with a mutation in the hot spot 1 of the FKS2 gene Developed after Prolonged Therapy with Caspofungin. Antimicrob Agents Chemother 56: 3417-3419.
42. Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, et al. (2011) Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother 55: 4880-4887.